Cardlytics' Q4 2021 financial results showed a 34.2% increase in total revenue to $90.0 million compared to Q4 2020. The company reported a net loss of $(11.8) million, or $(0.35) per diluted share. Billings increased by 42.6% to $134.0 million, and adjusted contribution rose by 48.5% to $44.0 million.
Total revenue increased by 34.2% to $90.0 million compared to Q4 2020.
Net loss attributable to common stockholders was $(11.8) million, or $(0.35) per diluted share.
Billings increased by 42.6% to $134.0 million compared to Q4 2020.
Cardlytics MAUs were 175.4 million, an increase of 7.2% compared to Q4 2020.
The company expects that a consistent, broad recovery across all verticals would enable it to exceed its expected long-term growth rate target of 30%.